Patented transdermal drug candidate from Vascarta may offer a convenient & cost-effective way to treat sickle cell disease
Press Releases
Vascarta Inc  
February 18, 2025

Patented transdermal drug candidate from Vascarta may offer a convenient & cost-effective way to treat sickle cell disease

SUMMIT, N.J., Feb. 18, 2025 /PRNewswire/ -- An article in the Proceedings of the National Academy of Sciences (PNAS) Nexus journal* by Goel et al. describes studies in which humanized

avatar profile Olean Times Herald

Olean Times Herald


Local & Social